In this article, we will take a look at some of the best high growth dividend stocks.
In 2024, macroeconomic uncertainty, election year volatility, and weakened consumer confidence led many corporations to adopt a more cautious approach, resulting in subdued dividend growth. Despite this challenging environment, emerging signs of recovery suggest that improved shareholder yield, through dividends, share repurchases, and debt reduction, may materialize in 2025.
The NASDAQ 100 Index, celebrating its 40th anniversary, has seen its constituents mature and generate substantial free cash flow, allowing multiple firms to initiate dividends for the first time. These new payouts accounted for over half of all US dividend declarations in early 2024.
Similarly, although S&P 500 dividend growth slowed in late 2024 due to political uncertainty, Ameriprise Financial’s projections indicate a rebound to 8% in 2025. Companies in sectors like information technology and consumer staples, known for high free cash flow and capital efficiency, are poised to increase shareholder distributions. Additionally, potential corporate tax reductions in 2025 could further enhance the outlook for shareholder returns.
In the current period of high investor enthusiasm driven by capital gains in artificial intelligence, it is essential to acknowledge the role dividends play in long-term portfolio performance. Historically, reinvested dividends have made up a substantial portion of total equity returns, accounting for approximately 55% of market gains between 1987 and the end of 2023. As markets enter a new phase, global equities seem poised for an era of robust dividend growth, supported not only by cyclical recovery but also by improved payout policies. Analysts now forecast a notable acceleration in global dividend per share growth, from a 20-year average of 5.6% annually to an anticipated 7.6% in the coming years.
With that in mind, let’s take a look at the 10 high growth dividend stocks that are also on Wall Street’s radar.
Image by Steve Buissinne from Pixabay
Our Methodology
We used the Finviz stock screener to filter out stocks that pay dividends and have an average 5-year revenue growth of over 10%. The 10 chosen stocks were some of the top high growth dividend stocks that also received coverage from Wall Street analysts and mainstream media outlets recently. These stocks were favored by top hedge funds in the first quarter of 2025, as per Insider Monkey’s Q1 2025 database.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (see more details here).
10. Equinor ASA (NYSE:EQNR)
Average 5-Year Revenue Growth Rate: 19.61%
Dividend Yield as of July 7: 9.71%
Number of Hedge Fund Holders: 18
Equinor ASA (NYSE:EQNR) is one of the best high growth stocks. Equinor, alongside its Fram partners, announced on June 26 plans to invest over $2 billion in a new deepwater development in the North Sea. The Fram Sør venture, backed by an investment of more than NOK 21 billion, will merge several offshore discoveries via a tieback to Troll C. Equinor filed its plan of development and operation with Minister Terje Aasland on June 26.
According to Geir Tungesvik, Equinor’s Executive VP for Projects, Drilling, and Procurement:
“Fram Sør will contribute to security of energy supply from the Norwegian continental shelf (NCS) to Europe. The development will put new oil and gas resources on stream by connecting new infrastructure to existing facilities that provide good and robust profitability…”
The development will drive engagement across Norway’s supply chain, generating around 4,500 full-time job positions during its execution. Equipped with fully electric subsea tree systems, the project aims to improve environmental performance and subsea visibility. Recoverable assets are estimated at 116 million barrels of oil equivalent, three-quarters of which is oil, and production is planned for the end of 2029.
Equinor ASA (NYSE:EQNR) is a globally integrated energy company engaged in the exploration, production, and distribution of petroleum and alternative energy sources.
9. Enterprise Products Partners L.P. (NYSE:EPD)
Average 5-Year Revenue Growth Rate: 13.34%
Dividend Yield as of July 7: 6.85%
Number of Hedge Fund Holders: 31
Enterprise Products Partners L.P. (NYSE:EPD) is one of the best high growth stocks. On June 23, UBS reiterated a Buy rating on EPD with a $40 price target. UBS has revised its Q2 2025 EBITDA forecast for Enterprise Products slightly downward from $2,516 million to $2,420 million. This adjustment reflects a combination of factors, including weaker MTBE-RBOB spreads, unplanned operational downtime at PDH1, seasonal declines in propane and natural gas demand, and a reduction in ethane exports to China.
Despite this modest downgrade, EPD continues to be viewed as a resilient income-generating asset, supported by a stable dividend yield and a consistent dividend growth for 27 consecutive years.
UBS forecasts a slight decline in the operating margin for the NGL Pipeline & Services segment in the second quarter of 2025, projecting $1,403 million compared to $1,418 million in the prior quarter. Despite this decline, the segment is expected to experience improved performance in the second half of the year, supported by the commissioning of two new gas processing plants, each potentially contributing an additional 40,000 to 50,000 barrels per day to natural gas liquids (NGL) volumes.
UBS anticipates an operating margin of $385 million for the Crude Pipeline & Services segment in the second quarter, reflecting a marginal increase from $374 million in the previous quarter. While earnings are believed to be nearing their cyclical lows, the firm expects current operational hindrances to persist through year-end, with a more pronounced earnings rebound projected in 2026.
The firm also expects a slight decline in Q2 operating margins, with Natural Gas Pipeline & Services at $354 million, down from $357 million, and Petrochemical & Refined Products at $312 million, down from $315 million, indicating stable but slightly weaker performance.
Enterprise Products Partners L.P. (NYSE:EPD) is a midstream energy company with an integrated infrastructure portfolio including pipelines, processing and fractionation facilities, storage assets, marine terminals, and marketing operations.
8. UBS Group AG (NYSE:UBS)
Average 5-Year Revenue Growth Rate: 10.56%
Dividend Yield as of July 7: 2.67%
Number of Hedge Fund Holders: 33
UBS Group AG (NYSE:UBS) is one of the best high growth stocks. On July 2, UBS Group disclosed that it plans to redeem two types of outstanding notes worth more than $3 billion.
The Swiss financial institution intends to repurchase $1.5 billion of its 6.373% Fixed/Floating Rate Senior Callable Notes maturing in 2026, with the final trading date set for July 11, 2025.
UBS also plans to call $1.575 billion of its 6.875% Tier 1 Capital Notes, with August 5, 2025, set as the final trading date.
The repurchase of the notes highlights a significant financial maneuver, amounting to nearly $3.075 billion in total debt retired.
UBS Group AG (NYSE:UBS) is a global financial institution providing a comprehensive range of banking, capital markets advisory, risk management, and multi-asset investment services to private, corporate, and institutional clients.
7. Huntington Bancshares Incorporated (NASDAQ:HBAN)
Average 5-Year Revenue Growth Rate: 11.43%
Dividend Yield as of July 7: 3.55%
Number of Hedge Fund Holders: 47
Huntington Bancshares Incorporated (NASDAQ:HBAN) is one of the best high growth stocks. On July 3, Wolfe Research upgraded HBAN to Outperform from Peer Perform with a price target of $21.
Wolfe Research’s upgrade indicates a positive outlook on Huntington’s net interest margin expansion prospects through 2026, supported by the favorable repricing of fixed-rate assets and the institution’s capacity to support loan growth with solid deposit accumulation.
In the aftermath of the March 2023 banking crisis, Huntington Bancshares has distinguished itself from peer institutions by achieving approximately 9% loan growth, while many of its competitors pursued balance sheet contraction as a risk mitigation strategy.
Over the same period, HBAN achieved approximately 14% growth in deposits, significantly outperforming its mid-cap peers by around 12 percentage points.
Wolfe Research estimates that Huntington has captured approximately 30 basis points of deposit market share since 2022, reflecting the bank’s competitive positioning within the sector. Over the past twelve months, Huntington’s revenue has grown by 5.2%, with analysts forecasting a further 15% increase in the current fiscal year, indicating strong underlying momentum.
Huntington Bancshares Incorporated (NASDAQ:HBAN) serves as the bank holding company for The Huntington National Bank, offering consumer, commercial, and mortgage banking solutions, including lending, deposit products, wealth and asset management, and capital markets.
6. Targa Resources Corp. (NYSE:TRGP)
Average 5-Year Revenue Growth Rate: 18.16%
Dividend Yield as of July 7: 2.33%
Number of Hedge Fund Holders: 55
Targa Resources Corp. (NYSE:TRGP) is one of the best high growth stocks. On June 26, RBC Capital lifted its price target from $191 to $205 and maintained an Outperform rating on the stock.
The price target was raised following a series of investor engagements with Targa executives, notably President Jennifer Kneale, Logistics & Transportation Head Scott Pryor, and IR and Fundamentals Vice President Tristan Richardson.
After the meetings, RBC Capital reported a moderately improved view of Targa Resources and highlighted a perceived misalignment between the firm’s market valuation and its robust financial position.
The company’s consistent cash distributions to shareholders were identified as a main element supporting the firm’s favorable outlook.
RBC Capital revised its 2026 projections for Targa Resources Corp. (NYSE:TRGP) upward, citing expected increases in volumes as the primary driver behind both the updated estimates and the elevated price target. The company has exhibited continued growth, with a five-year compound annual revenue growth rate of 14% and a solid EBITDA performance of $4.06 billion over the trailing twelve months.
Targa Resources Corp. (NYSE:TRGP) owns and operates a strategically integrated portfolio of midstream infrastructure assets across North America.
5. AstraZeneca PLC (NASDAQ:AZN)
Average 5-Year Revenue Growth Rate: 17.44%
Dividend Yield as of July 7: 2.23%
Number of Hedge Fund Holders: 56
AstraZeneca PLC (NASDAQ:AZN) is one of the best high growth stocks. Bloomberg reported on July 3 that AstraZeneca is engaged in negotiations with Summit Therapeutics Inc. (NASDAQ:SMMT) regarding a potential licensing agreement for an experimental lung cancer therapy, with the deal valued at up to $15 billion.
According to Bloomberg News, the potential deal may feature a multi-billion-dollar upfront payment to Summit along with subsequent milestone payouts. Nonetheless, the negotiations could collapse, or Summit may choose an alternative licensing collaborator.
The talks pertain to ivonescimab, a drug Summit gained access to under a separate December 2022 agreement with Chinese firm Akeso, worth up to $5 billion.
The company reported in May that ivonescimab, when used alongside chemotherapy in a Phase III trial, showed a favorable survival signal, but fell short of delivering a statistically significant outcome. Earlier findings from 2023 suggested that some patients with lung cancer had higher survival rates on the investigational drug than on Merck’s widely used Keytruda.
AstraZeneca PLC (NASDAQ:AZN) is a global biopharmaceutical company involved in the discovery, development, manufacturing, and commercialization of prescription medicines across a range of therapeutic areas, including oncology, cardiovascular, renal and metabolic diseases, respiratory and immunology, vaccines, and rare diseases.
4. Devon Energy Corporation (NYSE:DVN)
Average 5-Year Revenue Growth Rate: 28.95%
Dividend Yield as of July 7: 3.51%
Number of Hedge Fund Holders: 58
Devon Energy Corporation (NYSE:DVN) is one of the best high growth stocks. On June 4, Citi reiterated a Buy rating on DVN with a price target of $43. The decision is aligned with the firm’s recently announced $1 billion optimization plan and the operational updates provided during its Q1 earnings call.
A main focus in discussions surrounding Devon Energy Corporation (NYSE:DVN) is the potential impact of its optimization strategy on operational efficiency, capital intensity, and free cash flow per barrel by 2027. Supported by a 9.39% revenue growth rate and solid financial fundamentals, the company is well-positioned to execute its strategic objectives. Citi analysts have further evaluated how these metrics may compare with those of industry peers over the medium term.
Devon Energy’s strategic roadmap is designed to improve its financial performance through cost management and prudent capital allocation. These efforts are expected to enhance the firm’s competitive positioning within the broader energy sector, reinforcing its long-term operational and market resilience.
Citi’s Buy rating indicates confidence in Devon Energy’s long-term strategic direction, particularly as the company advances its financial objectives and operational optimization efforts. Stakeholders are expected to closely monitor the company’s execution amid the dynamic energy sector landscape.
Devon Energy Corporation (NYSE:DVN) is an independent American energy firm focused on the exploration and production of oil, natural gas, and natural gas liquids.
3. Blackstone Inc. (NYSE:BX)
Average 5-Year Revenue Growth Rate: 85.64%
Dividend Yield as of July 7: 2.66%
Number of Hedge Fund Holders: 81
Blackstone Inc. (NYSE:BX) is one of the best high growth stocks. On July 2, Bloomberg, citing sources close to the matter, reported that Blackstone Inc. (NYSE:BX) will take over Vista Equity’s minority position in Cvent Holding Corp for $1.3 billion.
The transaction represents Vista’s total departure from Cvent, following Blackstone’s $4.6 billion buyout in 2023, during which Vista had preserved a minority interest through a non-convertible preferred equity structure.
Vista initially acquired Cvent, a Virginia-based event management software company, in 2016 through a $1.7 billion transaction. During its ownership period, Cvent faced substantial operational challenges stemming from the COVID-19 pandemic, which severely disrupted the global events and hospitality sectors.
The company has regained momentum as the event industry rebounds, with conferences increasingly shifting toward hybrid formats that merge face-to-face and online experiences.
Blackstone Inc. (NYSE:BX) is a global alternative asset manager specializing in private equity, real estate, credit, and hedge fund strategies. The company is involved in many complex transactions including buyouts, growth equity, and structured credit, with a focus on long-term value creation.
2. AbbVie Inc. (NYSE:ABBV)
Average 5-Year Revenue Growth Rate: 12.31%
Dividend Yield as of July 7: 3.51%
Number of Hedge Fund Holders: 86
AbbVie Inc. (NYSE:ABBV) is one of the best high growth stocks. On June 30, Morgan Stanley maintained an Overweight rating and a $250 price target on AbbVie, in light of the company’s recent acquisition announcement.
Recently, AbbVie announced its intention to acquire Capstan Therapeutics, a clinical-stage biotechnology firm specializing in in-vivo cell engineering through RNA delivery platforms, for up to $2.1 billion in cash, contingent upon standard closing conditions. The company has a robust financial foundation, including a 71% gross profit margin and 5.45% year-over-year revenue growth, making AbbVie strategically positioned to integrate this acquisition and advance its innovation pipeline.
As part of the agreement, AbbVie Inc. (NYSE:ABBV) will gain access to CPTX2309, an in-vivo anti-CD19 CAR-T candidate currently undergoing Phase 1 clinical evaluation for B cell-mediated autoimmune disorders. The acquisition also includes Capstan’s proprietary lipid nanoparticle (LNP) platform, which enables targeted RNA delivery for the in-vivo engineering of specific cell populations.
According to Morgan Stanley, the deal represents a constructive step forward for AbbVie, enhancing its technological capabilities and reinforcing its pipeline in early-stage immunological research.
This move complements AbbVie’s previously outlined growth agenda, which forecasts expansion through 2032, with recent technology acquisitions offering critical optionality and pipeline diversification.
AbbVie Inc. (NYSE:ABBV) is a global biopharmaceutical company focused on the discovery, development, and commercialization of therapies including immunology, oncology, neuroscience, virology, and ophthalmology.
1. UnitedHealth Group Incorporated (NYSE:UNH)
Average 5-Year Revenue Growth Rate: 10.54%
Dividend Yield as of July 7: 2.92%
Number of Hedge Fund Holders: 139
UnitedHealth Group Incorporated (NYSE:UNH) is one of the best high growth stocks. On June 25, UBS reiterated a Buy rating on UNH but trimmed its price target for the stock to $385 from $400.
The revised price target follows statements made by UnitedHealth’s reinstated CEO during the company’s annual meeting on June 2, wherein he confirmed that updated 2025 guidance will be issued alongside the Q2 earnings report scheduled for July 29. Despite the adjustment, UnitedHealth, boasting a market capitalization of $273.56 billion, continues to demonstrate robust financial performance, with an 8.06% year-over-year revenue growth.
UBS noted that CEO Hemsley’s use of the word “prudent” to describe the upcoming outlook made analysts think the company might lower its earnings guidance from the earlier estimate of $22.50 per share. As more investors now expect earnings to be closer to $20 per share for 2025, UBS has adjusted its own forecast to match this new expectation.
UBS also lowered its profit expectations for Medicare Advantage, cutting the expected margin by 0.5% to 1.5%. The firm also reduced its forecast for Optum Health’s profit margin from 5% to 4.5%, showing a more cautious view of how well the business will perform in the near future.
UnitedHealth Group Incorporated (NYSE:UNH) delivers health benefit plans, clinical care and management, data analytics, and pharmacy solutions to a broad range of stakeholders, including individuals, employers, government entities, and healthcare providers.
While we acknowledge the potential of UNH to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than UNH and that has 100x upside potential, check out our report about this cheapest AI stock.
READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires.
Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email below.
